<DOC>
	<DOCNO>NCT01751321</DOCNO>
	<brief_summary>Glucose Variability With DPP-4 Inhibition</brief_summary>
	<brief_title>Glucose Variability With DPP-4 Inhibition</brief_title>
	<detailed_description>Patients Type 2 Diabetes , age 35-75y. , include double blind randomized placebo control study . The sample size 50 patient complete 30 day study period base statistical input Merck Research Laboratories , Rahway NJ .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes receive stable dose metformin â‰¥ 1500 mg HbA1c 7,5 % 10/0 % Type 1 diabetes HbA1c &lt; 7,5 % &gt; 10,0 %</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>